Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

舒立瑞 - NMPA Drug Approval Details

Approvals/NMPA/Eculizumab Injection

Approved

生物制品

Eculizumab Injection

Alexion Europe SAS🇨🇳 National Medical Products Administration

Approval Date: Jul 17, 2023
Approval ID: 8TELvAztFEB
Company: Alexion Europe SAS
Type: 生物制品

Approval Details

Approval Id: 8TELvAztFEB
Approval Number: 国药准字SJ20180023
Generic Name: 依库珠单抗注射液
Generic Name En: Eculizumab Injection
Trade Name: 舒立瑞
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 300mg/30mL
Reg Date: 2023-07-17
Expired Date: 2028-07-16
Company Name: Alexion Europe SAS
Company Detail Path: /organization/alexion-europe-sas

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 17, 2023

Approval ID

8TELvAztFEB

Type

生物制品

Back to NMPA Approvals